Aspire signed the agreement and they have to do th
Post# of 72447
Posted On: 07/14/2016 11:58:15 AM
Re: lousy.engineer #25243
Aspire signed the agreement and they have to do the deal whenever CTIX says so, no matter what the market conditions are.
They are not "risking" the trial because they have the money to get through this trial. The Prurisol trial is relatively simple -- give the people the stuff, measure the lesions, see if they have side effects. It doesn't involve all the really expensive kinds of tests that a Kevetrin trial requires. No X-rays, no MRI's, no expensive lab work. Just visual inspection/measurement, noting of any side effects, and patients' opinions of how their skin feels.
NNVC is a poor comparator. They've been in existence much longer than CTIX and have absolutely nothing to show for it except a laboratory funded on the backs of shareholders. Not a single clinical trial after all these years. CTIX has 5 clinical trials in progress, having spent far less shareholders' money than NNVC did. If I sound bitter it's because I lost money by buying NNVC and have absolutely no faith in that management. Or, for that matter, in their drug platform.
They are not "risking" the trial because they have the money to get through this trial. The Prurisol trial is relatively simple -- give the people the stuff, measure the lesions, see if they have side effects. It doesn't involve all the really expensive kinds of tests that a Kevetrin trial requires. No X-rays, no MRI's, no expensive lab work. Just visual inspection/measurement, noting of any side effects, and patients' opinions of how their skin feels.
NNVC is a poor comparator. They've been in existence much longer than CTIX and have absolutely nothing to show for it except a laboratory funded on the backs of shareholders. Not a single clinical trial after all these years. CTIX has 5 clinical trials in progress, having spent far less shareholders' money than NNVC did. If I sound bitter it's because I lost money by buying NNVC and have absolutely no faith in that management. Or, for that matter, in their drug platform.
(2)
(0)